Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802175 | 0.77 | CA12 (0.40) | — | |
| SCHEMBL29993215 | 0.76 | KCNJ1 (0.39) | HRH4MAOAMAOBALPLPTPN1 | |
| SCHEMBL7660043 | 0.76 | KCNJ1 (0.39) | HRH4MAOAMAOBALPLPTPN1 | |
| SCHEMBL16596449 | 0.74 | HRH4 (0.34) | HRH4MAOAMAOBALPLPTPN1 | |
| SCHEMBL12868653 | 0.72 | HRH4 (0.43) | HRH4SLC6A4MAOAMAOBALPL | |
| SCHEMBL3007597 | 0.71 | SLC6A4 (0.44) | HRH4SLC6A4MAOAMAOBALPL | |
| SCHEMBL27757778 | 0.71 | HRH4 (0.42) | HRH4SLC6A4MAOAMAOBALPL | |
| SCHEMBL4704298 | 0.70 | MAPK1 (0.43) | HRH4SLC6A4MAOAMAOBALPL | |
| SCHEMBL16952339 | 0.70 | HRH4 (0.39) | HRH4SLC6A4MAOAMAOBALPL | |
| SCHEMBL20303638 | 0.70 | HRH4 (0.39) | HRH4SLC6A4MAOAMAOBALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | HRH4 652/4885SLC6A4 1213/4885MAOA 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.